| 000 | 01115 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250515072708.0 | ||
| 264 | 0 | _c20070827 | |
| 008 | 200708s 0 0 eng d | ||
| 022 | _a1176-6344 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBarst, Robyn J | |
| 245 | 0 | 0 |
_aA review of pulmonary arterial hypertension: role of ambrisentan. _h[electronic resource] |
| 260 |
_bVascular health and risk management _c2007 |
||
| 300 |
_a11-22 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aEndothelin Receptor Antagonists |
| 650 | 0 | 4 |
_aEndothelin-1 _xblood |
| 650 | 0 | 4 |
_aExercise _xphysiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension, Pulmonary _xblood |
| 650 | 0 | 4 |
_aMuscle, Smooth, Vascular _xdrug effects |
| 650 | 0 | 4 |
_aPhenylpropionates _xpharmacokinetics |
| 650 | 0 | 4 |
_aPulmonary Wedge Pressure _xdrug effects |
| 650 | 0 | 4 |
_aPyridazines _xpharmacokinetics |
| 650 | 0 | 4 |
_aReceptors, Endothelin _xblood |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVascular Resistance _xdrug effects |
| 773 | 0 |
_tVascular health and risk management _gvol. 3 _gno. 1 _gp. 11-22 |
|
| 999 |
_c17120599 _d17120599 |
||